Graphite Bio Investor Relations Material
Latest events
M&A Announcement
Graphite Bio
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Graphite Bio Inc
Access all reports
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for diseases, primarily focused on therapies for serious and life-threatening diseases, in the United States. The company develops TALEN gene editing system for the treatment of various human diseases, including cancers. It is also involved in developing electroporation technology for drug and gene delivery.
Latest articles
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Anthony Noto: The Multifaceted CEO of SoFi
Anthony Noto built a successful and diverse career across multiple industries before becoming CEO of the fintech company SoFi.
9 Dec 2024
Master of Tickets: Breaking Down Live Nation Entertainment
Since merging in 2010, Ticketmaster and Live Nation have built an expansive ecosystem that dominates global live entertainment.
6 Dec 2024
Ticker symbol
GRPH
Country
🇺🇸 United States